Jyoti Bhagia
Child and Adolescent Psychiatry, Mayo Clinic, USA
Title: Treatment of ADHD and comorbid disorders in children and adolescents
Biography
Biography: Jyoti Bhagia
Abstract
ADHD is one of the most common neurodevelopmental disorders, affecting 7-11% of school age children and 9% of children between ages of 13-18 in the United States. ADHD has significant impact on school, home, social relationships and quality of life. It is also associated with increased financial burden due to healthcare costs.
ADHD guidelines are available for diagnosis and treatment of ADHD. There are many patients with ADHD who get diagnosed correctly and respond well to treatment. On the other hand, there are patients with ADHD who have significant comorbid disorders and do not respond to traditional treatment. Comorbid disorders presenting with ADHD include oppositional defiant disorder, learning disorders, disruptive mood dysregulation disorder, depression, anxiety, autism spectrum disorder, tic disorder, communication disorders, etc. There are several treatment guidelines for ADHD including the AACAP practice parameters, NICE guidelines, Texas Algorithm and others.
Studies have indicated medication as a treatment of choice for children with ADHD along with parent training. However, randomized controlled trials show that about 30% of children with ADHD do not benefit from medication. This could be due to phenotypic or genotypic differences or comorbid conditions.
Thus, the management of ADHD depends on the severity of ADHD and comorbid disorders and involves combined treatment with medications, therapy, behavior management strategies, social skills training and individualized education plans at school. Treatment must be individualized based on response, tolerability and side effects as well as age. Comorbid conditions like mood disorders may have to be treated before ADHD if symptoms significant effect psychosocial functioning.